Lisata Therapeutics, Inc.

LSE:0HS8 Stock Report

Market Cap: US$23.8m

Lisata Therapeutics Valuation

Is 0HS8 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0HS8 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0HS8's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0HS8's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0HS8?

Key metric: As 0HS8 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0HS8. This is calculated by dividing 0HS8's market cap by their current book value.
What is 0HS8's PB Ratio?
PB Ratio0.7x
BookUS$33.69m
Market CapUS$23.84m

Price to Book Ratio vs Peers

How does 0HS8's PB Ratio compare to its peers?

The above table shows the PB ratio for 0HS8 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.7x
HEMO Hemogenyx Pharmaceuticals
4.9xn/aUK£14.4m
AREC Arecor Therapeutics
5.7x-1.8%UK£28.9m
OPTI OptiBiotix Health
1.9xn/aUK£13.0m
PBX ProBiotix Health
6.2xn/aUK£7.9m
0HS8 Lisata Therapeutics
0.7x-3.2%US$23.8m

Price-To-Book vs Peers: 0HS8 is good value based on its Price-To-Book Ratio (0.7x) compared to the peer average (4.6x).

Price to Book Ratio vs Industry

How does 0HS8's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.48m
VAL ValiRx
0.6xn/aUS$2.80m
No more companies available in this PB range
0HS8 0.7xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0HS8 is good value based on its Price-To-Book Ratio (0.7x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0HS8's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0HS8 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0HS8's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0HS8 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$2.84
US$14.00
+392.9%
7.1%US$15.00US$13.00n/a2
Nov ’25US$2.87
US$14.00
+388.7%
7.1%US$15.00US$13.00n/a2
Oct ’25US$2.92
US$14.50
+397.2%
3.4%US$15.00US$14.00n/a2
Sep ’25US$2.98
US$14.50
+386.6%
3.4%US$15.00US$14.00n/a2
Aug ’25US$3.35
US$14.50
+332.8%
3.4%US$15.00US$14.00n/a2
Jul ’25US$3.68
US$14.50
+294.1%
3.4%US$15.00US$14.00n/a2
Jun ’25US$3.16
US$14.50
+359.6%
3.4%US$15.00US$14.00n/a2
May ’25n/a
US$14.50
0%
3.4%US$15.00US$14.00n/a2
Apr ’25n/a
US$14.50
0%
3.4%US$15.00US$14.00n/a2
Mar ’25US$3.15
US$14.50
+360.6%
3.4%US$15.00US$14.00n/a2
Feb ’25US$2.83
US$15.50
+447.7%
3.2%US$16.00US$15.00n/a2
Jan ’25US$2.85
US$15.50
+444.2%
3.2%US$16.00US$15.00n/a2
Dec ’24US$2.17
US$15.50
+615.0%
3.2%US$16.00US$15.00n/a2
Nov ’24US$2.03
US$15.50
+662.0%
3.2%US$16.00US$15.00US$2.872
Oct ’24n/a
US$15.50
0%
3.2%US$16.00US$15.00US$2.922
Sep ’24US$2.48
US$15.50
+525.0%
3.2%US$16.00US$15.00US$2.982
Aug ’24US$3.19
US$15.50
+385.9%
3.2%US$16.00US$15.00US$3.352
Jul ’24US$3.60
US$15.50
+331.0%
3.2%US$16.00US$15.00US$3.682
Jun ’24n/a
US$15.50
0%
3.2%US$16.00US$15.00US$3.162
May ’24n/a
US$15.50
0%
3.2%US$16.00US$15.00n/a2
Apr ’24US$3.33
US$15.50
+366.0%
3.2%US$16.00US$15.00n/a2
Mar ’24US$3.11
US$15.50
+398.4%
3.2%US$16.00US$15.00US$3.152
Feb ’24n/a
US$15.50
0%
3.2%US$16.00US$15.00US$2.832
Jan ’24US$2.43
US$30.00
+1,135.1%
50.0%US$45.00US$15.00US$2.852
Dec ’23n/a
US$30.00
0%
50.0%US$45.00US$15.00US$2.172
Nov ’23n/a
US$30.00
0%
50.0%US$45.00US$15.00US$2.032

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.65

7D

3.6%

1Y

-24.5%

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.21

7D

-3.8%

1Y

4.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$754.96

7D

2.0%

1Y

-7.1%